SARS-CoV-2 Infection, Vaccination and Risk of Death in People with An Oncological Disease in Northeast Italy.
COVID-19
risk of death
tumors
vaccination
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
29 Aug 2023
29 Aug 2023
Historique:
received:
07
08
2023
revised:
28
08
2023
accepted:
28
08
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
People with a history of cancer have a higher risk of death when infected with SARS-CoV-2. COVID-19 vaccines in cancer patients proved safe and effective, even if efficacy may be lower than in the general population. In this population-based study, we compare the risk of dying of cancer patients diagnosed with COVID-19 in 2021, vaccinated or non-vaccinated against SARS-CoV-2 and residing in Friuli Venezia Giulia or in the province of Reggio Emilia. An amount of 800 deaths occurred among 6583 patients; the risk of death was more than three times higher among unvaccinated compared to vaccinated ones [HR 3.4; 95% CI 2.9-4.1]. The excess risk of death was stronger in those aged 70-79 years [HR 4.6; 95% CI 3.2-6.8], in patients with diagnosis made <1 year [HR 8.5; 95% CI 7.3-10.5] and in all cancer sites, including hematological malignancies. The study results indicate that vaccination against SARS-CoV-2 infection is a necessary tool to be included in the complex of oncological therapies aimed at reducing the risk of death.
Identifiants
pubmed: 37763101
pii: jpm13091333
doi: 10.3390/jpm13091333
pmc: PMC10532764
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministero della Salute
ID : Ricerca Corrente 2023
Déclaration de conflit d'intérêts
The authors declare that the research was conducted without any commercial or financial relationships construed as a potential conflict of interest.
Références
Lancet Oncol. 2022 Jul;23(7):865-875
pubmed: 35660139
Clin Epidemiol. 2020 Dec 08;12:1337-1346
pubmed: 33335428
Ann Oncol. 2021 Jun;32(6):787-800
pubmed: 33746047
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Nat Cancer. 2021 Dec;2(12):1321-1337
pubmed: 35121900
Eur J Cancer. 2022 Jan;160:243-260
pubmed: 34794855
Int J Environ Res Public Health. 2022 Dec 17;19(24):
pubmed: 36554878
Lancet Oncol. 2021 Dec;22(12):1669-1680
pubmed: 34741822
Clin Oncol (R Coll Radiol). 2023 Jul;35(7):e421-e433
pubmed: 37019693
Euro Surveill. 2023 Mar;28(13):
pubmed: 36995374
Int J Cancer. 2021 Jan 15;148(2):363-374
pubmed: 32683687
Epidemiol Prev. 2017 Mar-Apr;41(2 Suppl 1):1-244
pubmed: 28629213
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2
pubmed: 34214473
Lancet Oncol. 2021 Dec;22(12):1681-1691
pubmed: 34767759
Crit Rev Oncol Hematol. 2021 Jul;163:103365
pubmed: 34052423
JCO Glob Oncol. 2020 Jun;6:799-808
pubmed: 32511066
Euro Surveill. 2022 Mar;27(9):
pubmed: 35241215
Front Pharmacol. 2023 Jun 23;14:1144824
pubmed: 37426814
BMJ. 2022 Feb 10;376:e069052
pubmed: 35144968
Nat Cancer. 2020 Aug;1(8):784-788
pubmed: 35122051
Int J Cancer. 2021 Apr 16;:
pubmed: 33861870
Euro Surveill. 2021 Jun;26(25):
pubmed: 34169819
Nat Cancer. 2021 Dec;2(12):1305-1320
pubmed: 35121899
Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):323-329
pubmed: 33412825
Rev Recent Clin Trials. 2022;17(1):11-14
pubmed: 34967300
Cancer Epidemiol. 2023 Feb;82:102318
pubmed: 36566579
Cancer Med. 2021 Nov;10(21):7781-7792
pubmed: 34551210
J Cancer Policy. 2022 Sep;33:100338
pubmed: 35671919